Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Vera Therapeutics, Inc.
NASDAQ:VERAHealthcare · Biotechnology
+1.47%$30.98
AH$30.37-1.97%vs close
Mkt Cap$2.23B
Float63.21M
O/S72.06M
Vol
$ Vol
RVOL
Inst Own-
SI21.5%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$299.62M
Total Assets$734.73M
Free Cash Flow-$241.73M
Debt & Equity
Debt 11%
Equity 89%
Total Debt$77.31M
Total Equity$604.52M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in VERA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$734.73M
Liabilities$130.21M
Accounts Receivable$3.29M
Accounts Payable$21.9M
Inventory$0
PP&E (Net)$1.92M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | -$846K | $0 | $251K | $509K |
| Gross Profit | $0 | $0 | $0 | $846K | $0 | -$251K | -$509K |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $215.26M | $126.17M | $78.22M | $69.84M | $22.48M | $43.92M | $7.29M |
| Selling, General, and Administrative | $100.22M | $41M | $23.79M | $21.91M | $11.92M | $3.89M | $4.41M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $315.47M | $167.17M | $102.01M | $91.75M | $34.4M | $47.81M | $11.7M |
| Operating Income (EBIT) | -$315.47M | -$167.17M | -$102.01M | -$90.9M | -$34.4M | -$48.06M | -$11.96M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $7.53M | $7.63M | $3.79M | $992K | $20K | $166K | $51K |
| Interest Income | $24.48M | $20.71M | $7.98M | $1.75M | $15K | $8K | $159K |
| Other Income (Expense) | $15.86M | $15.02M | $6.02M | $1.85M | $1.79M | -$5.35M | $108K |
| Income Before Tax (EBT) | -$299.61M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M | -$11.85M |
| Income Tax Expense | $1K | $1K | $1K | $1K | $1K | $1K | $1K |
| Net Income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M | -$11.85M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 | -3.46 |
| Diluted EPS | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 | -3.46 |
| Weighted Average OS | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M | 3.71M | 3.42M |
| EBITDA | -$291.62M | -$144.42M | -$92.18M | -$88.91M | -$32.41M | -$52.99M | -$11.29M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $354.73M | $92.65M | $45.68M | $43.46M | $79.67M | $53.65M | $3.19M |
| Short-Term Investments | $359.86M | $548.21M | $115.03M | $71.19M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $714.59M | $640.85M | $160.72M | $114.65M | $79.67M | $53.65M | $3.19M |
| Accounts Receivable | $3.29M | $3.77M | $0 | $0 | $0 | $52K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.54M | $913K | $3.22M | $719K | $480K | $442K | $4K |
| Total Current Assets | $728.88M | $651.22M | $172.02M | $125.7M | $82.54M | $54.26M | $3.56M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $1.92M | $4.33M | $3.04M | $5.22M | $0 | $0 | $1.39M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $11K | $58K | $867K | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.93M | $131K | $471K | $455K | $344K | $293K | $422K |
| Total Long-Term Assets | $5.85M | $4.46M | $3.52M | $5.74M | $1.21M | $293K | $1.82M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M | $54.55M | $5.38M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $21.9M | $7.67M | $11.12M | $11.99M | $1.39M | $909K | $342K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.37M | $0 | $4.82M | $0 | $377K | $960K | $220K |
| Total Current Liabilities | $53.45M | $25.37M | $22.3M | $25.6M | $7.69M | $2.41M | $1.06M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $74.84M | $50.69M | $49.88M | $24.81M | $4.92M | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $286K | $286K | $1.54M | $141.5M | $40.86M |
| Total Long-Term Liabilities | $76.76M | $53.16M | $51.56M | $28.93M | $6.47M | $141.5M | $40.87M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $130.21M | $78.53M | $73.86M | $54.53M | $14.16M | $143.9M | $41.93M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $71K | $64K | $44K | $28K | $21K | $0 | $0 |
| Retained Earnings | -$760.87M | -$461.25M | -$309.1M | -$213.11M | -$124.06M | -$91.45M | -$38.03M |
| Comprehensive Income & Other | $786K | $393K | $251K | -$224K | -$0 | $0 | $0 |
| Other Stockholders' Equity | $1.37B | $1.04B | $410.74M | $289.99M | $193.63M | $2.1M | $1.49M |
| Total Equity | $604.52M | $577.15M | $101.69M | $76.91M | $69.59M | -$89.35M | -$36.55M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M | $54.55M | $5.38M |
| Supplementary Data | |||||||
| Total Debt | $77.31M | $54.64M | $53.71M | $31.29M | $4.92M | $2K | $132K |
| Net Debt | -$277.42M | -$38.01M | $8.03M | -$12.17M | -$74.75M | -$53.65M | -$3.06M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M | -$11.85M |
| Depreciation & Amortization | $468K | $105K | $21K | -$846K | $176K | $251K | $509K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$1.8M | $0 | $0 |
| Stock-Based Compensation | $37.93M | $20.8M | $11.49M | $8.89M | $3.01M | $331K | $263K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $159K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $13.91M | -$3.45M | -$873K | $10.61M | $475K | $567K | -$291K |
| Other Working Capital | $9.08M | $6.11M | -$5M | -$3.86M | $3.04M | -$444K | $648K |
| Total Working Capital Change | $22.99M | $2.66M | -$5.87M | $6.75M | $3.51M | $123K | $516K |
| Other Non-Cash Items | -$2.88M | -$6.1M | -$1.84M | $6.67M | $4M | $17.9M | $277K |
| Net Cash from Operating | -$241.1M | -$134.68M | -$92.18M | -$67.6M | -$23.71M | -$34.81M | -$10.29M |
| Investing Activities | |||||||
| Capital Expenditures | -$630K | -$972K | -$63K | -$62K | $0 | -$99K | -$125K |
| Acquisitions | $0 | $0 | $0 | $70K | $796K | $0 | $0 |
| Purchases of Investments | -$310.45M | -$711.99M | -$224.93M | -$148.49M | $0 | $0 | $0 |
| Sales of Investments | $506.16M | $278.96M | $185.56M | $78M | $0 | $0 | $0 |
| Other Investing Activities | -$800K | $8.97M | $0 | -$70K | -$5M | $57K | $0 |
| Net Cash from Investing | $194.29M | -$425.03M | -$39.43M | -$70.55M | -$4.2M | -$42K | -$125K |
| Financing Activities | |||||||
| Debt Repaid | -$23.34M | - | -$24.74M | -$19.82M | -$4.92M | -$5.47M | $188K |
| Common Stock Issuance | $307.48M | $632.54M | $115M | $86.13M | $51.18M | $0 | $0 |
| Common Stock Repurchases | $0 | -$13K | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$21.92M | -$25.85M | -$6.2M | -$4.01M | -$2.21M | -$182K | $51K |
| Net Cash from Financing | $308.9M | $606.67M | $133.54M | $101.93M | $53.88M | $85.29M | -$137K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $262.08M | $46.97M | $1.93M | -$36.22M | $25.97M | $50.44M | -$10.55M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$241.1M | -$134.68M | -$92.18M | -$67.6M | -$23.71M | -$34.81M | -$10.29M |
| Capital Expenditure | -$630K | -$972K | -$63K | -$62K | $0 | -$99K | -$125K |
| Free Cash Flow | -$241.73M | -$135.65M | -$92.24M | -$67.66M | -$23.71M | -$34.91M | -$10.41M |
| Cash at Beginning | $92.65M | $45.68M | $43.75M | $79.97M | $54M | $3.56M | $14.11M |
| Cash at End | $354.73M | $92.65M | $45.68M | $43.75M | $79.97M | $54M | $3.56M |